SARS-Cov-2 Report 12 June 2020 Contents

José Luis Pires SARS-Cov-2 Report 12 June 2020 Contents

SARS-Cov-2 ➢ Confirmed cases by Country ➢ Deaths by Country ➢ Total confirmed Covid-19 cases and deaths per million people ➢ Daily new confirmed Covid-19 cases and deaths per million people (new) ➢ Covid-19 Projections – Portugal (new) ➢ Portugal, Lisbon, Loures, Macau, New Jersey, Cork - Cases by day and Total ➢ Reported infections per 1 million people for select countries with over 100 reported cases ➢ New cases vs 7-day average ➢ Cases Curve Simulator ➢ The latest coronavirus updates and developments impacting the global pharmaceutical supply chain

US 2,023,347 Brazil 802,828 Russia 510,761 India 297,535 UK 292,860 Spain 242,707 Italy 236,142 France 192,493 Germany 186,691 Turkey 174,023 Canada 99,159 China 84,217 Belgium 59,711 Netherlands 48,458 Sweden 48,288 12 June 2020 5 June 2020 29 May 2020 22 May 2020 15 May 2020 8 May 2020 1 May 2020 24 April 2020 Singapore 39,850 Portugal 35,910 Switzerland 31,044 Argentina 27,373 Ireland 25,238 Philippines 24,175 Israel 18,701 Japan 17,230 Austria 17,034 Denmark 12,235 Korea 12,003 Norway 8,608 Morocco 8,537 Malaysia 8,369 Australia 7,289 Finland 7,064 Hungary 4,053 Last Updated at 12 June 2020, 9:33 AM Luxembourg 4,052 Thailand 3,129 by the Center for Systems Science and Engineering Greece 3,088 at Johns Hopkins University Croatia 2,249

https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 Estonia 1,970 : : Iceland 1,807 Lithuania 1,756

Source Slovenia 1,490 June 2020 Confidential Hovione © 2020 3 0 500,000 1,000,000 1,500,000 2,000,000 2,500,000 Coronavirus (SARS-CoV-2 / Covid-19) – Deaths by Country Note: Selected Countries, sorted by # of cases

120,000 113,820

100,000

80,000

60,000 Last Updated at 12 June 2020, 9:33 AM

by the Center for Systems Science and Engineering 40,919 41,364 at Johns Hopkins University 40,000 34,167 29,349 27,136

20,000 8,772 9,636 6,7058,498 8,071 4,763 4,638 6,0634,814 25 1,5041,9377651,7031,036300 922 674 593 277 242 211 118 102 325 555 110 58 183 106 69 10 74 109 0

Source: https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6

Portugal ranks as EU country with second highest number of new cases in last 14 days, per million people

1600 1516

1400

1200

1035 1000 902 852 808 815 792 783 754 750 800 724 712699 663657 633 638 643 598 603 595 549 540 553 600 515 514 521516 533 472 480 460 446 452 444 421 371 366377382 400 349 350 342 320 331 310 302 295 306 288 285304 297 294 260 264 252271 257 270 235 242 234 227226 228 219 223 219 200 194 181 183 178 175138 187 173 195 192 143 163 152165 200 117 7686 92 98 3457 2 2 2 3 4 8 9 9 21819 0 0

* Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/ * - recalculated numbers

40000 120% 36,180 33,969 35,910 35,30635,600 34,69334,885 31,946 34,351 35000 100% 33,26133,592 32,70032,895 30,200 32,20332,500 31,596 100% 31,00731,292 30,47130,62330,788 29,43229,66029,912 30000 28,81029,03629,209 27,91328,13228,31928,583 27,26827,40627,58127,679 26,715 25,70226,182 25,05625,35125,19025,28225,524 80% 24,02724,32224,505 25000 23,39223,864 22,797 21,98222,353 21,379 62% 20,863 20,206 19,685 20000 18,84119,022 60% 18,091 51% 17,448 50%50% 16,58516,934 15,987 45% 15,472 44%43% 44%44% 43% 15000 13,956 13,141 35%35% 30% 12,452 40% 32% 25% 11,27811,730 10,524 30% 29% 9,886 27% 9,034 10000 25% 8,251 22% 20%21% 7,443 18% 5,9626,40816% 15% 5,17015% 20% 4,268 5000 3,544 11%9%9% 11% 2,995 7% 6%7% 6% 6% 5% 2,0602,362 4% 6% 4% 1,2801,600 3%4% 3%4% 3%3%3%2%3% 3% 2% 6427851,020 2% 1% 2%2% 2%1%1%1% 1% 1%1%2%2%2%1%1% 1%1%1%1%1%1%1%1%1%1%1%1%0%1%1%1%1%1%1%1%1%1%1%1%1%1%1%1%1%1%1%1% 0%2 4 6 9 13213039415978112169245331448 0% 0% 0 0%

# of cases % increase

Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/

1400 13021284 1253 1227 1243 1211 1200 1208 118011731179117511771187 1172 1200 1146 1099 1095 10751084 1068 10421058 1040 1005995 980968 1000 936 892 874 855856 838 842 818 813 815797805 800 726 709 692680 673657649 628629 627 609608 571 576 550 600 536531 529 513510512 514 440 486 474471 445 418 432428 421414 417415 398 394 400 354 366 276 267270271 245251 245 230240 241226233228 229222228224 206 201203 218208 215213207204 191 188 188 188186182176172 172 156169 164 169 154150 200 139139 126 136 144143134136135127 73 107107114 120112112113 108 115108105 8989 89 103 112 101939284 616171 80787271666566636464 657070 4057 414748 58565858575855 213038 20202635 0 0 0 0 09 130 0 0 0 0 0 0 0 10 9 1817 0

Hospital Stable Hospital ICU

Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/

25000 22200 2174222002 2052621339 208072099521156 2007920323 189111955219869 1918619409 20000 18637 1809618349 1754917822

15000

10000 75907705 6430643164526452

4636 5000 3822 3013318231983328 249925492549 1505 207622582422 1289 1383 1465 1470151916471671168917121743 14471455147414791485149214971504 1146120112281277132913571389 10891105111411261135114411631175118411901203121812311247126312771302131613301342135613691396141014241436 73576291778582085488090392894897398910071023104310631074 380409435470504535567383599493629519657610687610714610 0 0 0 0 0 0 0 0 0 0 0 01 01 01 02 13 13 23 3 56 125 145 14232233224343604376100431194314043160431874320968246682667529575140311184345196205233266277277347 0

Total Confirmed Deaths Total Confirmed Recoveries

Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/

Portugal

12June 020

60 56 54 52

50 48

43 40 40 37 35 33 33 34 33 32 31 31 31 30 29 29 30 27 27 25 25 23 2323 22 21 21 20 19 18 20 17 17 17 17 15 14 13 12 12 11 11 11 11 10 10 9 9 9 9 9 8 8 8 8 8 8 10 7 7 7 6 5 5 4 4 4 3 3 2 2 2 1 1 0 0 0 0 0 0

1.apr 2.apr 3.apr 4.apr 5.apr 6.apr 7.apr 8.apr 9.apr

1.may 2.may 3.may 4.may 5.may 6.may 7.may 8.may 9.may

01.jun 02.jun 03.jun 04.jun 05.jun 06.jun 07.jun 08.jun 09.jun 10.jun 11.jun 12.jun

10.apr 11.apr 12.apr 13.apr 14.apr 15.apr 16.apr 17.apr 18.apr 19.apr 20.apr 21.apr 22.apr 23.apr 24.apr 25.apr 26.apr 27.apr 28.apr 29.apr 30.apr

24.mar 25.mar 26.mar 27.mar 28.mar 29.mar 30.mar 31.mar

10.may 11.may 12.may 13.may 14.may 15.may 16.may 17.may 18.may 19.may 20.may 21.may 22.may 23.may 24.may 25.may 26.may 27.may 28.may 29.may 30.may 31.may

Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/

1600 120% 1,383 104% 1,352 1400 1,331 1,288 100% 1,172 1,236 1,209 1,191 1200 1,147 1,114 1,089 1,066 982 1,043 1,009 80% 1000 934 894 863 828 802819 800 771 60% 715 678 642656 612 591604 559576 600 536 497505507 40% 453464464 408410420 386393400 400 369 315315315 20% 292292301303304 251257260 17% 17% 17% 221231240 14% 201212 20% 12%13% 13%1797%191196 12% 200 158 3% 8% 8%126130131134138 8% 8% 1011097%117 7% 6% 72 84 5%4%5% 5% 5% 4% 5% 5% 4% 4% 4%5% 4% 57 64 3% 2%3% 3% 4% 2% 3% 4% 2% 2% 2% 3%3%2% 2%3% 2% 4% 3%3%2%2%2%3%2% 2% 3% 2% 24 280%280%28 1% 1% 0% 1%0% 0%0% 2%2% 0% 0% 2%0% 1% 1% 2%2% 2%

0 0%

1.apr 2.apr 3.apr 4.apr 5.apr 6.apr 7.apr 8.apr 9.apr

1.may 2.may 3.may 4.may 5.may 6.may 7.may 8.may 9.may

01.jun 02.jun 03.jun 04.jun 05.jun 06.jun 07.jun 08.jun 09.jun 10.jun 11.jun 12.jun

10.apr 11.apr 12.apr 13.apr 14.apr 15.apr 16.apr 17.apr 18.apr 19.apr 20.apr 21.apr 22.apr 23.apr 24.apr 25.apr 26.apr 27.apr 28.apr 29.apr 30.apr

24.mar 25.mar 26.mar 27.mar 28.mar 29.mar 30.mar 31.mar

10.may 11.may 12.may 13.may 14.may 15.may 16.may 17.may 18.may 19.may 20.may 21.may 22.may 23.may 24.may 25.may 26.may 27.may 28.may 29.may 30.may 31.may

# of cases % increase

Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/

250 228

200

150

97 97 100 82 85 75 71 60 60 55 54 54 56 48 48 48 48 50 51 39 41 40 41 41 39 41 353839 40 38 50 34 34 32 36 3634 27 31 283031 31 26 20 1924 23 24 22 24 24 2024 1924 24 19 19 18 16 15 16 13 18 14 12 7 12 11 9 0 5 5 0 0 0 2 5

1.apr 2.apr 3.apr 4.apr 5.apr 6.apr 7.apr 8.apr 9.apr

1.may 2.may 3.may 4.may 5.may 6.may 7.may 8.may 9.may

01.jun 02.jun 03.jun 04.jun 05.jun 06.jun 07.jun 08.jun 09.jun 10.jun 11.jun 12.jun

10.apr 11.apr 12.apr 13.apr 14.apr 15.apr 16.apr 17.apr 18.apr 19.apr 20.apr 21.apr 22.apr 23.apr 24.apr 25.apr 26.apr 27.apr 28.apr 29.apr 30.apr

24.mar 25.mar 26.mar 27.mar 28.mar 29.mar 30.mar 31.mar

10.may 11.may 12.may 13.may 14.may 15.may 16.may 17.may 18.may 19.may 20.may 21.may 22.may 23.may 24.may 25.may 26.may 27.may 28.may 29.may 30.may 31.may -50

-100 -128

-150

Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/

3000 2,80370% 62% 2,789 2,751 2,555 2,700 2,640 2,5952,614 60% 2,536 2,486 52% 2,447 2,324 2,409 2500 2,3652,400 50% 2,2542,290 2,107 2,206 2,1462,1772,182 2,076 2,0182,046 1,962 40% 2000 1,9191,938 1,8351,871 29% 1,7911,811 1,7241,7351,737 1,6681,700 30% 1,627 1,5671,5671,5671,579 1,496 1,4471,465 1500 1,4061,4131,413 20% 1,346 1,2661,271 9% 3% 8% 7% 7% 8% 7% 8% 7%2% 1,1458%1,169 6% 5% 10% 3%4% 5% 4% 1,0331,0381,060 4% 3% 3%3% 2% 2%9961,0202% 2% 2% 2% 2% 3%3%2% 3% 2%3% 3% 2% 2%2% 2% 2%2%2% 2% 2%2% 0% 946962 1%0% 0% 0%0% 1% 0%0%1% 1%1%0% 1%1% 1%1% 1%1%1% 1%0%1% 1% 1%0% 1% 1%1% 1%1% 1000 890905 851867 797 0% 754773 681699 633 634654 594 594 546 505 -10% 500 366 284284 -20% 175187 -20%

0 -30%

1.apr 2.apr 3.apr 4.apr 5.apr 6.apr 7.apr 8.apr 9.apr

1.may 2.may 3.may 4.may 5.may 6.may 7.may 8.may 9.may

01.jun 02.jun 03.jun 04.jun 05.jun 06.jun 07.jun 08.jun 09.jun 10.jun 11.jun 12.jun

10.apr 11.apr 12.apr 13.apr 14.apr 15.apr 16.apr 17.apr 18.apr 19.apr 20.apr 21.apr 22.apr 23.apr 24.apr 25.apr 26.apr 27.apr 28.apr 29.apr 30.apr

24.mar 25.mar 26.mar 27.mar 28.mar 29.mar 30.mar 31.mar

10.may 11.may 12.may 13.may 14.may 15.may 16.may 17.may 18.may 19.may 20.may 21.may 22.may 23.may 24.may 25.may 26.may 27.may 28.may 29.may 30.may 31.may

# of cases % increase

Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/

450

400 391 400 386 370 345 350 335336 323 309 294 300 277 283 265 268 270 255 246 250 231 222 227 228 209 209 211 203 199 197 198 191 187 190186 193 200 177 178 184 166166 158 158 158 153 146 149 140 140 138 144 150 135136 129 131 120124 120 126 115 115 108 108 99 98 101 102 105 90 96 100 868486 83 89 76 73 74 63 65 55 62 43 50 38 35 39 37 2327 26 28 25 13 0 1 1 1 1 1 3 1 7 6 7 0

01.jun 02.jun 03.jun 04.jun 05.jun 06.jun 07.jun 08.jun 09.jun 10.jun 11.jun 12.jun

01.abr 02.abr 03.abr 04.abr 05.abr 06.abr 07.abr 08.abr 09.abr 10.abr 11.abr 12.abr 13.abr 14.abr 15.abr 16.abr 17.abr 18.abr 19.abr 20.abr 21.abr 22.abr 23.abr 24.abr 25.abr 26.abr 27.abr 28.abr 29.abr 30.abr

01.mai 02.mai 03.mai 04.mai 05.mai 06.mai 07.mai 08.mai 09.mai 10.mai 11.mai 12.mai 13.mai 14.mai 15.mai 16.mai 17.mai 18.mai 19.mai 20.mai 21.mai 22.mai 23.mai 24.mai 25.mai 26.mai 27.mai 28.mai 29.mai

03.mar 04.mar 05.mar 06.mar 07.mar 08.mar 09.mar 10.mar 11.mar 12.mar 13.mar 14.mar 15.mar 16.mar 17.mar 18.mar 19.mar 20.mar 21.mar 22.mar 23.mar 24.mar 25.mar 26.mar 27.mar 28.mar 29.mar 30.mar 31.mar

30.may 31.may

Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/

16000 120% 14,407

14,161 13,878 14000 100% 100% 13,608 13,07313,222 12,47312,818 100% 12,137 11,828 12000 11,493 10,320 11,14211,335 10,874 10,643 10,055 80% 9,778 10000 70% 8,878 9,4239,567 9,1069,292 8,688 8,3618,490 59%59% 8,0978,235 7,7677,951 8000 7,4947,647 60% 7,1667,2427,316 6,9357,093 50% 50% 6,641 6,1366,241 5,9396,0476,047 5,6955,815 6000 5,4355,5315,5565,593 38% 5,0935,1945,277 35% 35% 4,7094,896 40% 33% 4,4384,500 31% 4,2374,302 23% 3,9944,102 27% 19% 3,8213,8343,8413,896 4000 25% 3,451 22% 3,1853,224 20% 2,9043,070 2,513 16%16% 16% 2,2072,34716% 14% 15%14%1,998 20% 1,799 11% 1,57711%10% 11% 2000 9% 1,2871,478 9921,0821,110 7% 6%7% 6% 7% 6% 737852 4% 5%4%4% 4% 448534 3% 3%3%3% 3% 3% 2%2% 2% 2% 2% 2%2%3% 2%3%3%3%2%2% 3%3%3%3% 3% 243278364 1% 1% 2% 1% 2%2% 2%0%1%2% 2% 1%2% 1%1%1% 2%2% 2%2%2%2% 2%1%2% 2%1% 2%1% 2%2%2% 1 2 3 4 5 6 9 1017234673116142180 0%0% 0%

0 0%

01.jun 02.jun 03.jun 04.jun 05.jun 06.jun 07.jun 08.jun 09.jun 10.jun 11.jun 12.jun

30.may 31.may

# of cases % increase

Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/

1600 120% 1,516

1400 100% 96%97% 97% 91% 93% 92% 92% 92%92%91% 1200 90%90% 89%90% 87% 86%87% 87% 83% 1,035 81% 80% 79% 78% 1000 76%76% 75% 75% 902 73% 70%70% 68% 852 69% 815 792 808 64%64% 783 61% 800 754 750 59% 60% 724 712 58% 57% 699 56% 55% 52% 643 663 657 53% 50% 50% 460 633 638 47% 598 603 595 600 44% 549 540 553 515 514 521 516 533 43% 41% 39% 320 472 480 40% 38% 446 452 444 37% 37% 36% 36% 37% 421 33% 33% 400 32% 32%32% 32% 391 370 32%33%371 377382 386 400 30% 349 350 366 345 28% 29% 323 335331336 342 27% 302 27%26% 27%27% 295 306 294 304 297 309 294310 25% 24% 24% 25% 24% 288271 277285 268 270283270 260 22% 22% 264 252 265 257 255 246 235 22% 21% 227 21% 242 234 227226 223228228 231 203 20% 222 209 19% 209 20% 219 211219 200 20% 194 177191 199 18%181 187197 19% 183 178 178 187184 198190 186 193195 192 16% 16%166 16616% 16%17% 158 15%163 108 158 175 173 165 158 200 143 140 140 135 136 138 153 146 131152144 149 13% 117 115 115 108 12% 13%120124 73 120 138126129 11% 86 868486 90 99 98 10183 96 102 9289105 98 5776 63 65 62 7674 34 43 38 35 39 55 37 8 9 9 7186192327 26 28 6% 13 7 25 12 13 14 1 1 3 12 4% 3% 0

0 1% 0%0% 0%

1.jun 2.jun 3.jun 4.jun 5.jun

1.abr 2.abr 3.abr 4.abr 5.abr 6.abr 7.abr 8.abr 9.abr

1.mai 2.mai 3.mai 4.mai 5.mai 6.mai 7.mai 8.mai 9.mai

4.mar 5.mar 6.mar 7.mar 8.mar 9.mar

06.jun 07.jun 08.jun 09.jun 10.jun 11.jun 12.jun

10.abr 11.abr 12.abr 13.abr 14.abr 15.abr 16.abr 17.abr 18.abr 19.abr 20.abr 21.abr 22.abr 23.abr 24.abr 25.abr 26.abr 27.abr 28.abr 29.abr 30.abr

10.mai 11.mai 12.mai 13.mai 14.mai 15.mai 16.mai 17.mai 18.mai 19.mai 20.mai 21.mai 22.mai 23.mai 24.mai 25.mai 26.mai 27.mai 28.mai 29.mai 30.mai 31.mai

10.mar 11.mar 12.mar 13.mar 14.mar 15.mar 16.mar 17.mar 18.mar 19.mar 20.mar 21.mar 22.mar 23.mar 24.mar 25.mar 26.mar 27.mar 28.mar 29.mar 30.mar 31.mar

Lisbon and Tagus valley Portugal % of new cases

Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/

5000

4372 4391 4500 4229 4059 4124 3881 4000 3748 3733 3649 3663 36273563 3581 3489 35053478 3515 3500 3347 33823361 3327 3219 3150 3088 3027 2953 3000 2625 2668 2474 25382527 24082388 2500 22992262 2324 2196 2207 2150 1949 2000 1819 1745 1705 1631 1525 14471413 1386 1500 1297 1245 1247 114412011184 1187 1073 1050 1029 930 974 938 831 817 864 837 806 1000 727 798 764 672 627 587 557 550 473 523462 470 437 385 500 315 271333299 160 8089 148 1 0 3 2 5 4 8 6211929 0

Source: https://www.nj.com/coronavirus/2020/03/see-the-spread-of-nj-coronavirus-in-charts-map-sunday-march-22-2020.html

180000 165,816 90% 83% 162,530 82% 157,815 163,893164,164164,497164,796165,346 161,545162,068163,336 158,844159,608160,445160,918 151,472 155,764156,628 160000 153,104154,154155,092 80% 150,399152,719 74% 148,039149,013 72% 145,089146,334 142,704143,905 139,945140,743141,560 137,085138,532 140000 133,635135,454 70% 130,593131,890 126,744128,269 123,717 60% 121,190 118,652 116,264 120000 56% 113,856 60% 53% 109,038111,188 105,523 102,196 50% 50% 49%49% 99,989 95,865 100000 92,387 50% 44% 88,806 42% 85,301 81,420 38% 78,467 80000 36% 75,317 40% 68,82471,030 64,584 61,850 29% 28% 58,151 60000 26% 26% 54,588 30% 20% 24% 51,027 47,437 44,416 20% 20% 41,090 19% 37,505 40000 17%34,124 20% 15%29,89514% 12%25,590 22,255 10%10% 18,696 8% 8% 20000 16,636 7% 7%7%6% 7% 6% 10% 11,12413,386 5% 8,825 4% 4%4% 4%4%4%4% 3%3% 6,876 3% 2% 2%2%2%2%2%2%2% 2% 2,8443,6754,402 1% 1%1%1%1%1%1%1%1%1%1%1%1%1%1%1%1%1% 1%1%0%1%1%1%0%1% 0% 1 0 4 6 111523295069981782674277428901,3271,914 0% 0%0%0%0% 0%0%0%0%0%0%

0 0%

2.apr 4.apr 6.apr 8.apr

5.mar 7.mar 9.mar

2.may 4.may 6.may 8.may

01.jun 03.jun 05.jun 07.jun 09.jun 11.jun

10.apr 12.apr 14.apr 16.apr 18.apr 20.apr 22.apr 24.apr 26.apr 28.apr 30.apr

11.mar 13.mar 15.mar 17.mar 19.mar 21.mar 23.mar 25.mar 27.mar 29.mar 31.mar

10.may 12.may 14.may 16.may 18.may 20.may 22.may 24.may 26.may 28.may 30.may

# of cases % increase

Source: https://www.nj.com/coronavirus/2020/03/see-the-spread-of-nj-coronavirus-in-charts-map-sunday-march-22-2020.html

5 5

3 3 3 65 days since last reported case

2 2 22 2 22 22 2 2

11 1 111 11 11 111 1 1

00 00000 0 00000000000000000000000000000000000000 00 00 0

2.apr 4.apr 6.apr 8.apr

2.may 4.may 6.may 8.may

23.jan 25.jan 27.jan 29.jan 31.jan 02.fev 04.fev 06.fev 08.fev 10.fev 12.fev 14.fev 16.fev 18.fev 20.fev 22.fev 24.fev 26.fev 28.fev 01.jun 03.jun 05.jun 07.jun 09.jun 11.jun

10.apr 12.apr 14.apr 16.apr 18.apr 20.apr 22.apr 24.apr 26.apr 28.apr 30.apr

01.mar 03.mar 05.mar 07.mar 09.mar 11.mar 13.mar 15.mar 17.mar 19.mar 21.mar 23.mar 25.mar 27.mar 29.mar 31.mar

10.may 12.may 14.may 16.may 18.may 20.may 22.may 24.may 26.may 28.may 30.may

Source: https://www.ssm.gov.mo/Portal/portal.aspx?lang=pt

50 45 444444 45 43 42 414141 39 40 38 37

35 32 31 30 30 28 26 25 21 65 days since last reported case 19 20 18 17 15 15 13 12 11 101010101010101010101010101010101010101010101010101010101010101010101010101010 10 8 8 7 7 7 7 7 7 5 5 2 2 1 1

Jun Jun Jun Jun Jun

Jun

- - - - -

2.fev 4.fev 6.fev 8.fev

2.apr 4.apr 6.apr 8.apr

1 3 5 7 9

1.mar 3.mar 5.mar 7.mar 9.mar

2.may 4.may 6.may 8.may

23.jan 25.jan 27.jan 29.jan 31.jan 10.fev 12.fev 14.fev 16.fev 18.fev 20.fev 22.fev 24.fev 26.fev 28.fev

10.apr 12.apr 14.apr 16.apr 18.apr 20.apr 22.apr 24.apr 26.apr 28.apr 30.apr

11.mar 13.mar 15.mar 17.mar 19.mar 21.mar 23.mar 25.mar 27.mar 29.mar 31.mar

10.may 12.may 14.may 16.may 18.may 20.may 22.may 24.may 26.may 28.may 30.may

# of cases

Source: https://www.ssm.gov.mo/Portal/portal.aspx?lang=pt

936

701 657 629 630 631 597 577 553 548 527 500 480 445 424 430 426 402 401 390 388 377 386 376 370 365 359 345 343 325 331 330 302294 295 255 266 265 235 229 236 219 212 221 211 219 191 204 200 156 159 126 137 139 129 121 107 115 102 92 88 6974 76 76 73 77 54 64 64 5759 5966 3940 51 37 4639 4738 2720 282425 19

1 0 0 1 4 7 5 1 2 3109 10 9 9 8

1.apr 2.apr 3.apr 4.apr 5.apr 6.apr 7.apr 8.apr 9.apr

1.mar 2.mar 3.mar 4.mar 5.mar 6.mar 7.mar 8.mar 9.mar

1.may 2.may 3.may 4.may 5.may 6.may 7.may 8.may 9.may

29.fev 01.jun 02.jun 03.jun 04.jun 05.jun 06.jun 07.jun 08.jun 09.jun 10.jun 11.jun

10.apr 11.apr 12.apr 13.apr 14.apr 15.apr 16.apr 17.apr 18.apr 19.apr 20.apr 21.apr 22.apr 23.apr 24.apr 25.apr 26.apr 27.apr 28.apr 29.apr 30.apr

10.mar 11.mar 12.mar 13.mar 14.mar 15.mar 16.mar 17.mar 18.mar 19.mar 20.mar 21.mar 22.mar 23.mar 24.mar 25.mar 26.mar 27.mar 28.mar 29.mar 30.mar 31.mar

10.may 11.may 12.may 13.may 14.may 15.may 16.may 17.may 18.may 19.may 20.may 21.may 22.may 23.may 24.may 25.may 26.may 27.may 28.may 29.may 30.may 31.may

Source: https://geohive.maps.arcgis.com/apps/opsdashboard/index.html#/29dc1fec79164c179d18d8e53df82e96

30000 140%

25,142 25,238 24,391 24,841 117% 24,92924,99025,06225,06625,11125,16325,18325,20125,20725,21525,231 24,50624,58224,63924,69824,73524,80324,876 120% 25000 23,95624,04824,11224,20024,25124,315 23,401 22,99623,13523,24223,827 22,38522,54122,760 21,98322,248 100% 21,50621,772 20,83321,176 20,25320,612 100% 19,64819,877 20000 19,262 18,18418,561 17,607 16,671 80% 15,65216,040 15,251 14,758 15000 63% 13,980 13,271 12,547 60% 52% 11,479 10,647 43% 9,655 10000 42% 38% 31% 8,928 40% 32%31% 7,054 29% 6,574 26% 6,074 27% 25% 24% 5,709 23% 4,9945,364 4,3734,604 5000 18%18%16%17% 3,849 14% 15%15% 14% 3,2353,447 20% 2,910 12%14% 11% 2,4152,61511%11% 10%9% 1,8192,1218% 8%7% 8%7% 8% 8% 6% 1,3291,564 7% 5% 6%6% 6%5%6% 6% 9061,125 3% 4% 3% 4% 557683785 3%2% 2% 2%1%2%2%1%2%2%1%1%1% 1%1%1% 1%2% 1 0 3 6 131819212434437090129169223292366 1% 1%0% 1%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%0%

0 0%

1.apr 2.apr 3.apr 4.apr 5.apr 6.apr 7.apr 8.apr 9.apr

1.mar 2.mar 3.mar 4.mar 5.mar 6.mar 7.mar 8.mar 9.mar

1.may 2.may 3.may 4.may 5.may 6.may 7.may 8.may 9.may

29.fev 01.jun 02.jun 03.jun 04.jun 05.jun 06.jun 07.jun 08.jun 09.jun 10.jun 11.jun

10.apr 11.apr 12.apr 13.apr 14.apr 15.apr 16.apr 17.apr 18.apr 19.apr 20.apr 21.apr 22.apr 23.apr 24.apr 25.apr 26.apr 27.apr 28.apr 29.apr 30.apr

10.mar 11.mar 12.mar 13.mar 14.mar 15.mar 16.mar 17.mar 18.mar 19.mar 20.mar 21.mar 22.mar 23.mar 24.mar 25.mar 26.mar 27.mar 28.mar 29.mar 30.mar 31.mar

10.may 11.may 12.may 13.may 14.may 15.may 16.may 17.may 18.may 19.may 20.may 21.may 22.may 23.may 24.may 25.may 26.may 27.may 28.may 29.may 30.may 31.may

# of cases % increase

Source: https://geohive.maps.arcgis.com/apps/opsdashboard/index.html#/29dc1fec79164c179d18d8e53df82e96

100 90 90 87 82 78 80

70 67

59 60

5049 49 50 41 39 40 37 34 31 29 30 24 24 25 21 21 22 19 20 19 19 17 1717 20 15 15 13 12 12 10 10 10 1010 11 11 11 10 10 11 9 9 8 8 9 8 8 10 6 7 7 6 7 6 7 6 5 4 4 6 5 4 3 2 2 2 2 2 2 3 2 1 0 1 1 0 0 1

1.abr 2.abr 3.abr 4.abr 5.abr 6.abr 7.abr 8.abr 9.abr

1.mai 2.mai 3.mai

4.may 5.may 6.may 7.may 8.may 9.may

01.jun 02.jun 03.jun 04.jun 05.jun 06.jun 07.jun 08.jun 09.jun 10.jun 11.jun

10.abr 11.abr 12.abr 13.abr 14.abr 15.abr 16.abr 17.abr 18.abr 19.abr 20.abr 21.abr 22.abr 23.abr 24.abr 25.abr 26.abr 27.abr 28.abr 29.abr 30.abr

22.mar 23.mar 24.mar 25.mar 26.mar 27.mar 28.mar 29.mar 30.mar 31.mar

10.may 11.may 12.may 13.may 14.may 15.may 16.may 17.may 18.may 19.may 20.may 21.may 22.may 23.may 24.may 25.may 26.may 27.may 28.may 29.may 30.may 31.may

Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/

1800 20% 18% 1,532 1,521 18% 1600 1,5271,5281,5291,5291,5291,531 16% 1,5141,5171,517 1,4581,4641,4721,477 16% 1,4281,4381,4401,451 16% 1,3981,420 1,3721,3761,386 16% 1400 1,3461,3521,361 1,256 1,2321,2341,2381,249 1,2051,207 13% 1,1771,1921,1971,199 14% 13% 13% 1,1541,1561,1641,175 1200 1,1261,1361,146 1,1031,1101,125 1,0771,0871,096 12% 1,0471,053 11% 1,028 12% 10% 979 1000 10%945 10% 916 829 10% 780 800 8% 8% 7% 730 7% 7% 7% 8% 7% 648 7% 581 6% 600 6% 503 472 5% 6% 431 4% 4% 421 400 343362 4% 304 3% 4% 3% 272292 238255 2% 3% 208217 2% 184 2% 2% 154171 2% 200 123133 1% 1% 2% 101104 1%1% 1%1%1% 1%1% 1% 1%1% 1%1% 1% 1% 1% 1%1% 0% 1% 0% 1% 0% 1% 0%0%1%0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%0%0% 0%0%0%0%0%0%

0 0%

1.abr 2.abr 3.abr 4.abr 5.abr 6.abr 7.abr 8.abr 9.abr

1.mai 2.mai 3.mai

4.may 5.may 6.may 7.may 8.may 9.may

01.jun 02.jun 03.jun 04.jun 05.jun 06.jun 07.jun 08.jun 09.jun 10.jun 11.jun

10.abr 11.abr 12.abr 13.abr 14.abr 15.abr 16.abr 17.abr 18.abr 19.abr 20.abr 21.abr 22.abr 23.abr 24.abr 25.abr 26.abr 27.abr 28.abr 29.abr 30.abr

22.mar 23.mar 24.mar 25.mar 26.mar 27.mar 28.mar 29.mar 30.mar 31.mar

10.may 11.may 12.may 13.may 14.may 15.may 16.may 17.may 18.may 19.may 20.may 21.may 22.may 23.may 24.may 25.may 26.may 27.may 28.may 29.may 30.may 31.may

# of cases % increase

Source: https://covid19.min-saude.pt/ponto-de-situacao-atual-em-portugal/

June 3, 2020 June 10, 2020

(7-day average)

955839e06441

aeb3

11ea

48f8

- https://www.ft.com/content/a26fbf7e

June 2020 Confidential Hovione © 2020 33 Source: C C C C C C C New cases vs New cases vs New cases vs New cases vs New cases vs New cases vs New cases vs New cases vs New cases vs New cases vs New cases vs Total Total New daily cases: New daily cases: C C C o o o o o o o Country/City 7-day average 7-day average 7-day average 7-day average 7-day average 7-day average 7-day average 7-day average 7-day average 7-day average 7-day average cases deaths reported on 11 June 7-day avg o o o l l l l l l l 11 June 20202 4 June 202022 28 May 2020 21 May 2020 14 May 2020 8 May 2020 30 April 2020 23 April 20202 16 April 20202 9 April 2020 2 April 2020 l l l u u u u u u u Loures 1,352 21 29 Down Up Up Up Up Down Up Down Up Up Down Lisbon 2,789 38 36 Up Up Up Down Up Up Down Up Up Down Up Lisbon and Tagus V. 14,161 417 283 289 Down Up Up Up Up Down Up Up Up Up Up New Jersey 165,816 12,443 470 469 Up Down Up Down Down Down Down Up Up Up Up Cork 1,532 1 2 Down Down Down Down Up Down Up Down Up Up Up

Argentina 27,373 765 1141 920 Up Up Down Up Up Up Up Up Up Down Down Australia 7,289 102 0 5 Down Down Down Down Down Up Down Down Down Down Down Austria 17,034 674 34 33 Up Up Down Down Up Up Down Up Down Up Down Belgium 59,711 9,636 132 126 Up Down Down Down Down Down Down Down Up Down Down Brazil 802,828 40,919 32,091 26,303 Up Up Down Up Up Up Up Down Up Up Up Canada 99,159 8,071 409 558 Down Down Down Down Down Down Down Down Up Up Up China 84,217 4638 11 7 Up Down Down Down Down Down Down Down Down Up Down Croatia 2,249 106 2 0 Up Up Down Down Down Down Down Up Down Up Up Denmark 12,235 593 15 35 Down Down Up Up Down Up Up Up Down Up Up Estonia 1,970 69 11 11 Up Up Down Down Up Down Down Down Down Down Down Finland 7,064 325 15 18 Down Down Up Down Down Up Up Down Down Up Down France 192,493 29,349 397 412 Down Down Down Down Down Up Up Down Down Up Up Germany 186,691 8,772 555 379 Up Down Down Up Up Up Down Down Down Up Up Greece 3,088 183 10 19 Down Up Up Down Up Up Up Down Down Down Down Hungary 4,053 555 10 14 Down Down Down Up Up Down Down Up Down Up Down Iceland 1,807 10 0 0 Up Up Up Up Up Up Up Down Down Down Up India 297,535 8,498 9,996 9,951 Up Up Down Up Up Up Up Up Down Down Down Ireland 25,238 1703 16 17 Down Up Down Down Down Down Down Up Up Up Down Israel 18,701 300 179 150 Up Down Up Down Up Down Down Up Down Down Up Italy 236,142 34,167 202 275 Down Down Up Down Down Down Down Up Down Down Down

Japan average day 17,230 922 41 39 Up Down Down Down Down Down Down Down Down Up Up

Korea - 12,003 277 45 45 Up Down Up Down Up Down Down Down Down Down Down New cases cases New vs Lithuania 7 1,756 74 6 7 Down Down Down Up Up Down Down Down Down Down Up Luxembourg 4,052 110 3 4 Down Down Up Up Up Down Up Down Up Down Up Malaysia 8,369 118 2 53 Down Up Down Down Down Down Up Down Down Down Down Netherlands 48,458 6,063 184 193 Down Down Up Up Down Down Down Down Down Down Down Norway 8,608 242 13 19 Down Down Up Down Down Up Up Up Up Down Down Philippines 24,175 1036 740 569 Up Up Up Up Up Up Up Down Up Down Down Portugal 35,910 1,504 294 331 Down Up Up Up Down Up Down Down Down Down Up Russia 510,761 6,705 8,779 8,761 Up Down Down Down Down Up Up Down Up Up Up Singapore 39,850 25 451 366 Up Up Up Down Down Up Down Up Up Up Up Slovenia 1,490 109 2 3 Down Up Down Up Up Down Up Down Up Up Down Spain 242,707 27,136 314 279 Up Down Down Down Down Down Down Down Up Down Down Sweden 48,288 4,814 890 859 Up Up Up Up Up Up Up Up Down Up Up Switzerland 31,044 1,937 23 17 Up Up Down Up Down Down Down Down Up Down Down Thailand 3,129 58 0 3 Down Up Up Up Down Down Down Down Down Down Down Turkey 174,023 4,763 922 945 Down Down Up Down Up Up Up Down Down Up Up UK 292,860 41,364 1003 1,470 Down Up Down Down Down Up Down Down Down Up Up June 2020 Confidential Hovione © 2020 34 US 2,023,347 113,820 17,235 20,730 Down Up Up Up Down Down Down Down Down Up Up Cases Curve Simulator

• This COVID-19 Active Cases Curve Simulator has been developed by the IQVIA Data Science and Advanced Analytics team as a tool to help stakeholders make decisions based on the level and trajectory of active cases in their country, region or state

• The core of the model is the Susceptible-Exposed-Infectious-Removed epidemiology model, and inputs are from publicly available sources updated daily

• The simulator focuses on “total active cases” as a metric that speaks to the overall impact COVID-19 is having, not just limited to hospitalizations or deaths (where other models are focused, e.g. IHME). We believe the active cases curve will be used by public health officials – along with other considerations, such as availability of testing – to guide their decision- making on modifying stay-at-home rules

• Active cases are those confirmed diagnosed cases, excluded those that have recovered or died.

• The simulation shows the number of active cases (per population), shape of increase of the curve, timing of the apex of the curve and the shape and timing of the decline from the apex.

• Scenarios are labelled as “normal”, “optimistic” and “pessimistic” based on the following

• “Normal” scenario means the model parameters are derived to fit most closely to the actual reported public data

• “Optimistic” scenario is the lower bound, assuming people closely follow nonpharmaceutical interventions (NPIs), and reference what was achieved in other countries with similar characteristics

• “Pessimistic” scenario is the upper bound, assuming people do not closely follow NPIs and time from exposure to diagnosis takes longer than reported in the literature

Source: IQVIA, June 2020

• 11 June • SVB Leerink analyst Geoffrey Porges defended Gilead's right to profit off the only proven COVID-19 treatment, valuing remdesivir's sticker price at around $5,000 a course—close to the $4,460 cost proposed by drug pricing watchdog the Institute for Clinical and Economic Review. • Moderna has confirmed plans to enroll 30,000 patients in a randomized, placebo-controlled phase 3 study of its COVID shot candidate, mRNA-1273, beginning in July. • Singapore approves Gilead's remdesivir to treat Covid-19 • 10 June • The National Institutes of Health (NIH) plans to run large phase 3 trials of COVID vaccines from Moderna, AstraZeneca and J&J in the coming months, a government researcher told the Wall Street Journal. Moderna's phase 3 trial is slotted for July, followed by AstraZeneca's in August. Both shots are currently in phase 2 testing. • 9 June • A day after Bloomberg reported on the possible megamerger, sources told The Times of London that AstraZeneca had already lost interest in a tie-up with Gilead Sciences, choosing to focus on its own pipeline and COVID vaccine project instead. • Back in April, the National Institutes of Health released trial results from Gilead Sciences showing that its antiviral remdesivir prevented lung disease in monkeys infected with COVID-19. On Tuesday, those results were confirmed in a peer-reviewed publication in the medical journal Nature. Meanwhile, countries have been closely tracking remdesivir's performance in the clinic as they aim to fast-track approval for the drug in COVID patients. • The European Medicines Agency (EMA) received Gilead Science's long-awaited marketing application for remdesivir. The EMA will study the drug in patients with COVID-19 on a reduced timeline, and said it has a jump start thanks to a rolling review of data it completed May 15. • 8 June • The Biomedical Advanced Research and Development Authority (BARDA) updated its contract with Moderna to scale up production of the drugmaker's experimental COVID vaccine, mRNA- 1273, at additional U.S. manufacturing suites once it exits the clinic. The shot is in phase 2 trials now, and Moderna is working with BARDA and the National Institutes of Health to hammer out plans for phase 3.

• 4 June • The European Union has plans to use a $2.7bn emergency fund for advance purchasing of promising Covid-19 vaccine candidates, reported Reuters citing EU officials. • SVB Leerink upgraded its expectations for remdesivir as more countries pin their hopes on Gilead's antiviral to treat COVID-19. In a note to investors, SVB Leerink said it expects remdesivir sales and government stockpiling to turn a profit—and at a price of about $5,000 per patient in the U.S. • Ebola drug remdesivir endorsed as a coronavirus treatment in Australia. The antiviral drug remdesivir has been recommended for the treatment of Covid-19 patients in Australia, by the national taskforce bringing together the country’s peak health groups. • 3 June • The Lonza Group, recruited by Moderna to manufacture COVID vaccines, says it could complete two of its commercial manufacturing lines ahead of schedule. Lonza hopes to supply small batches of active ingredients for Moderna's experimental vaccine by July, and announced its Portsmouth, New Hampshire and Visp, Switzerland lines should be ready to make ingredients by the end of the year—a month ahead of projections. • Moderna has started dosing participants in each age cohort of its Phase II clinical trial of its Covid-19 vaccine candidate, mRNA-1273. The trial, which is expected to involve 600 healthy participants, will assess a 50μg and a 100μg dose of the vaccine. • NIAID director Anthony Fauci said the phase 3 trial for Moderna's experimental COVID-19 vaccine will begin in July. The tests will mainly take place in the U.S., focusing on a wide range of patient ages, but Fauci added the company also plans to enroll 30,000 patients in trials abroad • South Korea granted emergency approval for Gilead Science's remdesivir on Wednesday, joining a host of countries looking to bring the antiviral to COVID patients. South Korea's Ministry for Food and Drug Safety approved five daily doses for moderately ill patients and 10 days of treatment for patients on oxygen support. • 2 June • The New York Times has reported that five vaccine finalists have been selected for the US Government’s Operation Warpspeed. The five companies selected were Moderna, AstraZeneca-University of Oxford, Johnson & Johnson (J&J), Merck and Pfizer. Moderna and AstraZeneca’s vaccines are both in Phase II, while Pfizer’s candidate, which is being developed with BioNTech, is in Phase I/II trials. J&J and Merck are both earlier along in the development process. • Indian drugmakers are eager for government approval to start making remdesivir under license from Gilead Sciences, but pricing and dosage are two major holdups. • Last week, Gilead’s remdesivir received its first positive scientific opinion from the Medicines and Healthcare products Regulatory Agency under the Early Access to Medicines Scheme for use in Covid-19 patients. • 1 June • Gilead Sciences released top-line data from its phase 3 Simple trial for remdesivir in COVID-19 patients with pneumonia, but without reduced oxygen levels. Patients who took a 5-day course of remdesivir were 65% more likely to show signs of clinical improvement compared with patients who received standard care, the company said.

• 28 May • Oxford Biomedica penned a one-year clinical and commercial supply deal with AstraZeneca to scale up manufacturing for the COVID-19 vaccine candidate AZD1222. • Roche announced a new partnership with Gilead as the drugmakers started a phase III study testing the Swiss drugmaker's immunology med Actemra/RoActemra alongside Gilead's antiviral remdesivir to treat COVID-19. Roche plans to begin enrollment in June, with a target of 450 patients globally. • Moderna expanded a 2016 deal with Swiss pharmaceutical ingredient maker CordenPharma on Thursday to secure large quantities of lipids for its experimental COVID-19 vaccine mRNA- 1273. The deal grants access to two additional CordenPharma manufacturing sites in France and the U.S. as Moderna looks to boost its vaccine stores in anticipation of success in the clinic. • GlaxoSmithKline (GSK) has announced it will manufacture one billion doses of its pandemic adjuvant by 2020. Although GSK is not producing its own Covid-19 vaccine, it is supporting on a non-profit basis other companies who are with its pandemic adjuvant. During previous flu pandemic, this part of the vaccine, which boosts the immune response, was shown to reduce the amount of protein needed per dose, therefore allowing more doses to be produced. • 27 May • The World Health Organization is putting a stop to global studies into the effectiveness of hydroxychloroquine after repeated safety concerns. The decision came following a study published in The Lancet that showed patients who took hydroxychloroquine were at higher risk of death and heart problems than those who did not. • 26 May • Gilead's remdesivir has shown promising results, but some limits, too. Detailed data published in the New England Journal of Medicine showed that on average, hospitalized patients receiving remdesivir recovered a median of four days faster than patients on placebo, with mortality in the remdesivir group at 7.1% compared to the placebo group's 11.9%. But the data also suggest the drug offers more benefits to patients on oxygen therapy than to the critically ill on mechanical ventilators. • The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted early access to remdesivir in its medicines scheme for conditions with a high unmet medical need. • 25 May • Like all industries, the pharma industry has been disrupted by the Covid-19 pandemic. The generics industry has been impacted particularly by supply chain problems and huge surges in demand for existing medicines. • Accord’s head of scientific affairs Dr Anthony Grosso explains how the industry has worked to overcome these challenges and respond to the needs of patients, as well as become more prepared for future healthcare emergencies. • 24 May • Experts across world continue to highlight the need to reopen economies to limit the economic upheaval caused by the Covid-19 pandemic. • However, some believe that unless testing capabilities are ramped up, reopening the economy may result in an upsurge in infection rate.

• 22 May • Beximco Pharma launches first generic remdesivir for Covid-19, under the brand name Bemsivir. • 21 May • AstraZeneca has secured over $1 billion from the HHS' BARDA for the development and supply of the Oxford University vaccine it has partnered on. • Moderna is currently the leader in the mRNA vaccine space, but Evercore ISI analyst Umer Raffat is raising doubts about the strength of the preliminary phase 1 data the biotech recently posted. • AstraZeneca has previously also invested in Moderna. • The unemployment rate in the US currently stands at 14.7% but for people aged between 20 and 24, the rate increases to 25.7%, according to statistics provided by the BLS. • 20 May • People with Type 1 diabetes are three and a half times more likely to die than non-diabetics who catch COVID-19 while Type 2 patients are twice as likely to die than non-diabetics, NHS England has found. • 19 May • Gilead Sciences has pledged to donate its current supply of 1.5 million doses of remdesivir, of which 607,000 vials are being allocated to the U.S. government. Now, the biotech is increasing its U.S. donation to about 940,000 doses by June. • The Trump administration has signed a $354 million four-year deal with with a new Virginia company called Phlow to produce generic drugs and APIs needed to treat COVID-19 in an effort to bring pharma manufacturing back to the U.S. • Meanwhile, Cipla, which is one of four drugmakers with nonexclusive remdesivir licensing deals, is also looking at combo treatment options for COVID-19, including teaming Fujifilm's flu drug Avigan (favipiravir) with the Gilead med. • 18 May • Moderna shares leapt as the company unveiled early phase 1 data showing its vaccine candidate, mRNA-1273, elicited neutralizing antibodies in eight trial participants available for analysis. Based on the data, The company said its own phase 2 trial will be amended to study two dose levels, 50 µg and 100 µg. • On the heels of unveiling early results for its mRNA vaccine, Moderna plans to raise $1.34 billion through a stock sale to help produce the shot if it crosses the regulatory finish line. • Moncef Slaoui, the newly appointed U.S. coronavirus czar, will divest his $10 million in Moderna stock options, which shot up in value Monday after the company unveiled promising early data. • 17 May • The EU could grant Gilead's remdesivir an conditional nod in the "coming days," EMA head Guido Rasi said on Monday at a hearing at the EU Parliament in Brussels.

• 14 May • After a fast-tracked approval, Japan has already started distributing Gilead Sciences' remdesivir to hospitals. The drug is being used for patients in intensive care or on ventilators. • The United Nations’s International Labour Organization predicts 1.6bn informal economy workers could suffer “massive damage” to their livelihoods. • In the second quarter of 2020, Covid-19 may cost the equivalent of 305 million full-time jobs. • Current G7 jobless totals vary widely, from 30 million in the United States to 1.76 million in Japan. • McKinsey believe that Europe’s CEOs will have to draw on the region’s spirit of innovation to recover post Covid-19. • 13 May • The US Food and Drug Administration (FDA) has granted fast track designation to Moderna’s Covid-19 vaccine candidate, mRNA-1273. • Even if Moderna succeeds with its unproven vaccine platform, the biotech won't be able to make enough doses for the entire world, CEO Stephane Bancel said. • After Gilead inked a series of licensing deals for remdesivir, Public Citizen argued the drug should be in the public domain. • 12 May • Gilead inked licensing deals with generic drugmakers Cipla, Ferozsons Laboratories, Hetero Labs, Jubilant Lifesciences and Mylan allowing those companies to manufacture and distribute remdesivir in 127 countries, royalty-free. • The European Medicines Agency expanded its compassionate use guidelines for Gilead's remdesivir. Originally, the drug was recommended for patients requiring mechanical ventilation. It's now recommended for certain hospitalized patients. • 11 May • Physicians and hospitals have already expressed frustrations about the difficulty obtaining Gilead Sciences' remdesivir. Now, an HHS distribution plan shows that only 607,000 vials of the emergency use drug will be made available to U.S. patients over the next six weeks, out of a total donation of about 1.5 million • 9 May • Gilead Sciences may have been the target of Iranian hackers using fake email login pages to access confidential data, Reuters reported. In one case, a fake login page was sent to a legal and corporate affairs executive in April. Reuters couldn't confirm whether the attack was successful. • Speaking of Gilead, the National Institutes of Health will pair the drugmaker's COVID-19 antiviral remdesivir with Eli Lilly's rheumatoid arthritis drug Olumiant in a new study in U.S. hospitalized patients. The trial will eventually enroll 1,000 patients across 100 sites, the NIH said. • After the FDA's emergency use authorization, Gilead donated its entire stockpile of remdesivir to the government for further distribution. But the drug hasn't reached those most in need, according to Axios. "Some went to the wrong places, some went to the right places," one senior Trump administration official said. "We don't know who gave the order. And no one is claiming responsibility."

• 8 May • Hydroxychloroquine has failed an observational study in New York. According to a paper published in The New England Journal of Medicine, researchers found no significant difference between hydroxychloroquine and standard care in terms of patients' need for ventilation or death rate. • After the FDA's emergency use authoriziation, Gilead has donated its entire stockpile of remdesivir to the government for further distribution. • FDA authorises Moderna to conduct Phase II trial of Covid-19 vaccine • 7 May • Gilead Sciences' remdesivir won approval in Japan as Veklury. It's the first full global nod for the COVID-19 treatment following the U.S. emergency use authorization last week. Authorities in Japan approved the drug under an "exceptional approval" regulatory pathway. • Gilead spent about $50 million on remdesivir manufacturing scale-up and clinical trial costs during the first quarter. • Moderna is planning an "imminent" start to a 600-participant phase 2 trial of its mRNA vaccine candidate, mRNA-1273, after the FDA cleared its trial protocol. The company's goal is to initiate a phase 3 study "early this summer" and win approval as soon as 2021. • 6 May • Gilead Sciences says it’s in licensing talks with the “world’s leading chemical and pharmaceutical manufacturing companies” about their ability to produce remdesivir for countries in Europe, Asia and beyond until at least 2022. • Scientists have identified a new strain of the coronavirus that appears to be more contagious than the early versions in the pandemic, according to a new study led by scientists at Los Alamos National Laboratory. • 5 May • A drugmaker in Bangladesh, Beximco, plans to start making Gilead's newly FDA-authorized remdesivir for $59 to $71 per vial, Reuters reports. The company is planning to produce the drug for domestic use, at least initially. It isn't clear whether Beximco had a licensing deal to manufacture the product. • 4 May • How much should Gilead Sciences charge for remdesivir? Up to $4,460 per patient, according to the Institute for Clinical and Economic Review. But even at $1,000 per patient—less than a quarter of ICER's pitched price—Gilead could theoretically rake in $1 billion in sales, as it looks to build a supply capable of treating 1 million patients by the end of the year. • 2 May • Moderna Therapeutics has tapped Lonza to help manufacture the biotech's mRNA vaccine candidate, dubbed mRNA-1273.

• 30 April • Economic Outlook: Covid-19 puts 1.6 billion jobs at risk – Q1 company earnings ‘most watched in history’ say Goldman Sachs. • GDP of majority of the economies to be below pre-Covid-19 levels for two to three years. • Gilead’s remdesivir meets endpoint in NIAID study. • GlobalData Epidemiologist Report – Covid-19 now affects 187 countries – over 1 million cases in US • 29 April • The US economy has contracted at an annual rate of 4.8%, the steepest slump since the 2008 recession. This brings the longest ever period of economic expansion in the US to an end. • It is predicted that gross domestic product (GDP) could drop by 30% in the next quarter, as many “stay-at-home” measures were only implemented at the end of this quarter, with a sharp rise in unemployment also anticipated. • 28 April • On the back of disappointing results for Sanofi and Regeneron’s IL-6 inhibitor, Kevzara yesterday, a research team from the Assistance Publique-Hôpitaux de Paris announced that an open- label, randomized, controlled study of Roche’s Actemra in 129 moderate to severe COVID-19 patients with pneumonia was successful. • UK Approves Clinical Trial Of Plasma Therapy for COVID-19. • Covid-19’s impact on drug contract manufacture in Italy. GlobalData’s Contract Service Provider database shows there are 148 CMOs with Italian facilities • 27 April • Another high profile drug being repurposed for COVID-19 treatment faced a major setback this morning. Sanofi and Regeneron’s IL-6 inhibitor, Kevzara showed no benefit in “severe” COVID-19 patients requiring oxygen therapy. • China has granted approval to assess a third coronavirus vaccine candidate against COVID-19 in the second phase of clinical trials. • Vaccine major Serum Institute of India on Sunday said it plans to start production of the COVID-19 vaccine developed by Oxford University in the next two to three weeks and hopes to bring it to the market by October if the human clinical trials are successful. • France, Italy and Spain announce easing of lockdown measures. • 24 April • On April 23rd, news broke of a potential failure of Gilead's COVID-19 candidate, remdesivir, to improve mortality in hospitalized adult patients with severe COVID-19 from a trial in China. However, any data reported here must be approached with caution, as the full results of the study have not yet been made available, and what has been released is from a trial which was terminated due to difficulties in recruitment.

• 23 April • Gilead’s remdesivir has failed to show benefit in a clinical trial conducted to treat Covid-19 patients in China, according to data the WHO accidentally posted on its website. • Preliminary reports from epidemiological studies suggest that countries with universal BCG vaccination programs have been impacted less by Covid-19 • 22 April • The Covid-19 pandemic is expected to widen the gap between the poor and rich creating massive inequality and high unemployment rates. • The world is on track for a recession of “unprecedented depth in the post-war period”, ratings agency Fitch says with world gross domestic product to tumble by 3.9% in 2020. • 21 April • Pharma CEOs are asking that governments pour out billions of dollars in advance for the development and production of potential COVID-19 drugs. • Following other companies such as Pfizer and Novo Nordisk, Merck & Co. is now also expanding its patient assistance program, allowing eligible patients to get its medicines at no cost. • To ease shortages of drugs for COVID-19 patients who are on ventilators, the FDA is now allowing small compound pharmacies to temporarily fill the supply gap. • 20 April • Researchers at the NIH and Gilead have published results from an animal trial of remdesivir, involving 12 rhesus macaques, showing that early antivrial treatment reduced COVID-19 symptoms and lung damage. • Though the COVID-19 pandemic has upended the public markets—and thrown a wrench into what was expected to be a stellar IPO season—the biotech industry could be that particular cloud’s silver lining, as investors look toward additional windows and opportunities later this year. • A congressman is calling on the SEC to investigate last week’s leak of remdesivir data, along with its impact on the stock market and a 15% boost in Gilead’s share price. Though the antiviral is not supposed to be a moneymaker for the Big Pharma, news following its development has added billions to Gilead’s market cap. • The FDA has granted emergency use authorizations to four antibody diagnostics—also known as serology tests—that promise to help identify individuals who have been exposed to the novel coronavirus. • 19 April • Meanwhile, in the U.S., the FDA has stepped up seizures of prescription drugs being sent to American customers from Canada and other countries, where they are sold at cheaper prices, according to Kaiser Health News. • 18 April • In the European region, it’s notable that the number of cases are increasing in Belgium with a total of 34,809 cases, placing the country in rank just after the UK, though the gap between the two countries is large.

• 17 April • BARDA supports Moderna’s vaccine. • Promise of Gilead’s remdesivir made clear. • Nasal spray vaccine on the horizon. • 16 April • Millions of doses of hydroxychloroquine donated to the U.S. by Bayer have come under scrutiny after the quality of the drug's Indian and Pakistani active pharmaceutical ingredients and finished doses may have never passed FDA inspections, sources told Reuters. Bayer has donated 3 million tablets of the drug, called Resochin, to the U.S. national stockpile for treatment of COVID-19. • Despite the fact that Fujifilm's Avigan hasn't been proven as an effective COVID-19 treatment, Japan and China are providing the drug to other countries, the Wall Street Journal reports. • 15 April • India is hoping to rapidly expand its production of global active pharmaceutical ingredients to compete with China's dominance in the market amid COVID-19 lockdowns, Bloomberg reported. The country is one of the largest providers of generic drugs to the U.S. • Gilead Sciences is among the companies with promising COVID-19 drugs and the company has now applied for a trademark for potential remdesivir packaging. But at press time, the company's shares were down on word that a second China trial had been stopped for lack of enrollment. • As the White House's Tuesday press briefing, President Donald Trump said the U.S. is halting funding to the World Health Organization. Bill Gates and others blasted the move. • 14 April • China's National Medical Products Administration has greenlit two inactivated COVID-19 vaccines to start human testings. • Sanofi and GSK, two of the world’s biggest vaccine makers, are joining forces to develop a recombinant DNA vaccine, aiming to enter clinical testing in the second half of 2020. • 13 April • Rutgers University has received the FDA’s first emergency authorization for a COVID-19 diagnostic that uses easy-to-collect saliva samples instead of the more difficult deep nose swabs. • Gilead provided results from 53 severe COVID-19 patients treated with remdesivir on a compassionate use basis in a paper published in The New England Journal of Medicine. During a median follow-up of 18 days, 36 patients (68%) had a clinical improvement, and the mortality rate was 18% among patients receiving invasive ventilation. Jefferies analysts argue the data "suggest remdesivir may work and is generally safe." • 10 April • Gilead's promising COVID-19 drug candidate remdesivir could be made at $9 per treatment, while the estimated manufacturing cost for generic hydroxychloroquine stands as little as $1 per course, a study published in the Journal of Virus Eradication found.

• 9 April • Pfizer says a Phase 2 investigator-initiated study for the use of tofacitinib, a JAK inhibitor, in patients with SARS-CoV-2 interstitial pneumonia is about to start in Italy. • Mylan says its expedited manufacturing of hydroxychloroquine has resulted in stocks being available ahead of schedule. • Analysts at Morningstar say the coronavirus pandemic will affect Big Pharma and Big Biotech companies in two major ways: an economic slowdown, likely causing a 4.6% hit to 2020 global GDP (implying a 1.4% decline in 2020), and a disruption in the use of drugs, vaccines, and consumer healthcare products. “However, the highly inelastic demand for most drugs should largely offset any recessionary impact,” they add. • 8 April • The European Commission publishes its guidelines on the optimal and rational supply of medicines to avoid shortages during the COVID-19 outbreak. • US Food and Drug Administration commissioner Stephen Hahn says that since the agency issued its policy to allow developers of serological tests to identify patients that have developed an immune response to market them without FDA review, over 70 tests are available for use. • 7 April • Bristol Myers Squibb announces an expansion of its patient support programs to help unemployed US patients who have lost their health insurance due to the COVID-19 pandemic. • 6 April • India lifts export restrictions on 12 APIs and their formulations including antibiotics, vitamins and hormones with immediate effect, according to a Directorate General of Foreign Trade notification. Paracetamol and hydroxychloroquine are notable omissions from the list. • Thermo Fisher Scientific says that due to the COVID-19 pandemic, it is withdrawing its 2020 annual financial guidance, which was provided on January 30. “As the pandemic spread from China to countries worldwide, the company saw a significant reduction in customer activity by late March. • 4 April • In an open letter, Gilead CEO Daniel O’Day says the biotech company has managed to reduce the end-to-end manufacturing timeline for its antiviral remdesivir – which has shown potential to treat patients with severe COVID-19 -- from one year to around six months. • India’s Directorate General of Foreign Trade announces an immediate blanket ban on exports of hydroxychloroquine “without any exceptions.”

• 3 April

• Generics industry association Medicines for Europe supports a call by the European University Hospital Alliance for European coordinated efforts to prevent shortages of ICU medicines – which include sedatives, muscle relaxants, antibiotics and anaesthetics -- amid rising demand.

• Novartis says it plans to start a clinical trial of its JAK inhibitor, Jakavi (ruxolitinib), in patients with COVID-19 associated cytokine storm, a form of severe immune overreaction that can result from coronavirus infection.

• 2 April • Roche Canada announces its COVID-19 Innovation Challenge, a competition to bring forward innovative ideas to fight the pandemic. • Amgen and Adaptive Biotechnologies announce a partnership to develop neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19. • The US Food and Drug Administration approves Celularity’s Investigational New Drug application for its CYNK-001 cell therapy in adults with COVID-19. • The European Medicines Agency says chloroquine and hydroxychloroquine, currently authorised for malaria and certain autoimmune diseases but being investigated for their potential to treat COVID-19, should only be used in clinical trials or emergency use programmes. • 1 April • AbbVie is donating USD35 million to support COVID-19 relief efforts. • Gilead announces that it has started two Phase 3 studies of its investigational antiviral treatment, remdesivir, in patients with moderate to severe COVID-19 in the UK. • The US Food and Drug Administration says it has launched a program to speed up the development of treatments for COVID-19. • 31 March • The US government is in discussions with India over a possible relaxing of restrictions on API exports from India imposed at the start of March. • China is stepping up its efforts to produce and ship APIs with a focus on meeting international demand, particularly for those showing potential to treat the COVID-19 disease • 30 March • In a letter to customers, CordenPharma says it has halted routine manufacturing at its Bergamo facility in northern Italy for one week from 26 March to 1 April due to supply chain interruption and staffing issues. • Novartis announces that its generics unit Sandoz has started to ship 30 million doses of hydroxychloroquine to the US Department of Health and Human Services for use in clinical studies to test its effectiveness in people who have tested positive for COVID-19.

• 27 March

• Sanofi and Translate Bio are collaborating to develop a novel mRNA vaccine candidate against COVID-19, extending an existing 2018 agreement between the two firms on mRNA vaccines for infectious diseases.

• Wuxi Biologics says more than 98% of its staff are now back at work after the country’s recent lockdown. The Chinese CDMO says it has received “a surge of requests” in March for new projects, predominantly from clients outside of China.

• 26 March • The proposed merger Mylan and Pfizer’s generics division, Upjohn, is postponed until the second half of 2020 due to the COVID-19 pandemic. Mylan’s EGM has been pushed back two months to 30 June. • A consortium of fifteen biopharma companies have agreed to share their proprietary libraries of drugs that already have promising safety and activity data with the COVID-19 Therapeutics Accelerator launched by the Gates Foundation, Wellcome, and Mastercard to quickly screen them for potential against COVID-19. The firms include BD, Boehringer Ingelheim, bioMerieux, Eisai, Eli Lilly, Gilead, GSK, Johnson & Johnson, Merck & Co., Merck KGaA, Novartis, Pfizer and Sanofi. • Mylan waives its right to a 180-day marketing exclusivity period in the US to distribute its generic version of antiretroviral Kaletra (lopinavir/ritonavir) to help increase the available supply of the product should it prove effective in treating patients with COVID-19.

• 25 March • Medicines for Europe says export restrictions (including some within the EU) on drug and ingredients manufacturers is undermining European production. The generics industry body says its mid-February request for effective coordination between manufacturers and authorities to manage the crisis has not been fully realized. “We deeply regret that this process is not yet fully operational at EU or at national level except in Italy,” it says. • Vir Biotechnology announces that it has identified multiple human monoclonal antibody (mAb) development candidates that neutralize SARS-CoV-2, the virus responsible for COVID-19. The firm expects human trials to begin within 3-5 months. • Suven Pharmaceuticals warns customers it cannot export finished products due to a shortage of raw materials following India’s recent lockdown to fight COVID-19.Suven Pharmaceuticals warns customers it cannot export finished products due to a shortage of raw materials following India’s recent lockdown to fight COVID-19. • CDMO Catalent reaffirms it has not identified any significant risk or delay that may have a substantial effect on delivery of products or clinical trial supplies.

• 24 March

• Switzerland-headquartered CDMO Siegfried is supplying disinfectant in the Swiss and German regions where it operates production sites. It says it will not supply private or commercial organizations.

• In a letter to customers, CDMO CordenPharma says it has instructed all employees to cancel all business travel and face-to-face meetings until the end of April. It says all its manufacturing facilities in Italy, Germany, France, Switzerland and the US are fully operational.

• CMO Argonaut Manufacturing Services says it is ready to provide services for pre-clinical to Phase III manufacturing of vaccines and therapeutics, including those for firms working toward a COVID-19 vaccine or therapeutic under accelerated timelines.

• 23 March • The International Generic and Biosimilar medicines Association, representing generic and biosimilar manufacturers, urges governments to reopen air freight routes to ensure access to medicines during the COVID-19 pandemic. • Roche’s Genentech in collaboration with the Biomedical Advanced Research and Development Authority says the FDA has approved a Phase III clinical trial of its arthritis drug Actemra (tocilizumab) to treat hospitalized adult patients with severe COVID-19 pneumonia. • Eli Lilly becomes the first Big Pharma company to announce its clinical trials are being adversely affected by coronavirus. The firm says it is delaying most new study starts and pausing enrollment of new patients or volunteers “to ease the burden on participating healthcare facilities.” • 22 March

• Gilead says it is no longer accepting requests for emergency access to its antiviral remdesivir due to an “exponential increase” in such requests and “overwhelming demand.”

• 21 March • The Indian government approves a USD1.8 billion scheme to boost production of APIs and medical devices. The plan involves development of three mega API drug parks in partnership with states and financial incentives to manufacturers of 53 identified critical APIs on incremental sales for the next six years. • In a filing to the Bombay Stock Exchange, Ipca Laboratories says the US FDA has lifted an import alert on its hydroxychloroquine sulphate and chloroquine phosphate APls and hydroxychloroquine sulphate tablets due to the shortage implications of coronavirus. • Bristol Myers Squibb says it has now implemented a mandatory work from home policy for its workforce. “All employees, contingent workers and contractors who can do their jobs from home must do so,” it says.

• https://en.wikipedia.org/wiki/Timeline_of_the_2019%E2%80%9320_Wuhan_coronavirus_outbreak • https://www.seattletimes.com/seattle-news/health/coronavirus-timeline-how-the-outbreak-unfolded/ • https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 • https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports • https://www.pharmaceutical-technology.com/news/coronavirus-a-timeline-of-how-the-deadly-outbreak-evolved/ • https://www.cphi-online.com/updated-covid19-pharma-tracker-news082415.html • https://www.dgs.pt/em-destaque.aspx